SHANGHAI, Jan. 31, 2023 - Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autologous GPRC5D-directed CAR-T cell therapy, in the treatment of relapsed/refractory multiple myeloma (RRMM) in an article entitled “Phase 1 Open-Label Single-Centre Single Arm Study of GPRC5D CAR T Cells(OriCAR-017) in Patients with Relapsed/Refractory Multiple Myeloma (POLARIS)” in The Lancet Haematology (2022 impact factor: 30.153).
Shanghai, Oct. 25, 2022 -- Oricell Therapeutics (Shanghai) Co., Ltd. ("Oricell" or "the company”) announced that the United States (U.S) Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation (ODD) to Oricell's proprietary CAR-T cell therapy targeting GPRC5D (OriCar-017) for the treatment of Relapsed/Refractory Multiple Myeloma (R/R MM).
SHANGHAI, Sep. 21, 2022 -- OriCell Therapeutics (Shanghai) Co., Ltd. ("OriCell" or "the Company”) has formally received a license from China’s National Medical Products Administration (NMPA) for its Ori-C101 Investigational New Drug (IND) application according to information from NMPA. Obtaining the license signals that OriCell’s first proprietary CAR-T product targeting Glypican-3 (GPC3) for the treatment of advanced liver cancer is ready for domestic clinical trials.
OriCell Therapeutics raises over $120 million in series B binancing led by Qiming Venture Partners and Quan Capital to advance cell therapies for cancer immunology. 2022 is set to be a milestone year for OriCell who has been focusing on the field of cancer immunotherapy for more than seven years and is fully committed to becoming an innovative global drug developer.
Shanghai, PRC, June 5th, 2022 — OriCell Therapeutics Co., Ltd (OriCell) today reported the positive results from Phase I POLARIS study, an investigator-sponsored study evaluating Ori-CAR017, an autologous GPRC5D-directed CAR-T cell, in patients with relapsed/refractory multiple myeloma at American Society of Clinical Oncology(ASCO) annual meeting.
Shanghai, PRC, May 26, 2022—OriCell Therapeutics Co., Ltd (OriCell) today announced that an abstract detailing data from a Phase I study evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (POLARIS) will be presented an oral session at the upcoming 2022 ASCO Annual Meeting on Sunday, June 5th.
OriCell Therapeutics announced the newest data from a Phase I study evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (POLARIS) has been accepted by the 27th European Hematology Association Congress, and detailed information will be presented in an oral seesion. OriCAR-017 is a CAR-T product with a novel target based on OriCell's independently developed Ori®Ab and Ori®CAR technology platform.
OriCell Therapeutics announced the newest clinical data of the independently developed product OriCell targeting Relapsed/Refractory Multiple Myeloma(RRMM) has been selected by ASCO 2022. The detailed data will be reported in oral presentation.
沪公网安备 31011502019994号